Please use this identifier to cite or link to this item:
Title: Bone marrow biopsy superiority over PET/CT in predicting progression-free survival in a homogeneously-treated cohort of diffuse large B-cell lymphoma.
Authors: Chen-Liang, Tzu-Hua
Martín-Santos, Taida
Jerez, Andrés
Rodríguez-García, Guillermo
Senent, Leonor
Martínez-Millán, Cristina
Muiña, Begoña
Orero, Mayte
Teruel, Anabel
Martín, Alejandro
Gómez-Espuch, Joaquín
Kennedy, Kyra
Benet, Carmen
Raya, José María
Fernández-González, Marta
de la Cruz, Fátima
Guinot, Marta
Villegas, Carolina
Ballester, Isabel
Baile, Mónica
Moya, María
López-Jiménez, Javier
Frutos, Laura
Navarro, José Luis
Uña, Jon
Fernández-López, Rosa
Igua, Carolina
Contreras, José
Sánchez-Vañó, Raquel
Cozar, María Del Puig
Tamayo, Pilar
Mucientes, Jorge
Sánchez-Blanco, José Javier
Pérez-Ceballos, Elena
Ortuño, Francisco José
Keywords: Bone marrow biopsy;PET/CT;diffuse large B-cell lymphoma;outcomes research
metadata.dc.subject.mesh: Adolescent
Age Factors
Aged, 80 and over
Antibodies, Monoclonal, Murine-Derived
Antineoplastic Combined Chemotherapy Protocols
Bone Marrow
Disease-Free Survival
Follow-Up Studies
Health Status
Lymphoma, Large B-Cell, Diffuse
Middle Aged
Multivariate Analysis
Positron Emission Tomography Computed Tomography
Predictive Value of Tests
Retrospective Studies
Survival Rate
Young Adult
beta 2-Microglobulin
Issue Date: 27-Sep-2017
Abstract: Several studies have reported uneven results when evaluating the prognostic value of bone marrow biopsy (BMB) and PET/CT as part of the staging of diffuse large B-cell lymphoma (DLBCL). The heterogeneity of the inclusion criteria and not taking into account selection and collinearity biases in the analysis models might explain part of these discrepancies. To address this issue we have carried a retrospective multicenter study including 268 DLBCL patients with a BMB and a PET/CT available at diagnosis where we estimated both the prognosis impact and the diagnostic accuracy of each technique. Only patients treated with R-CHOP/21 as first line (n = 203) were included in the survival analysis. With a median follow-up of 25 months the estimated 3-year progression-free survival (PFS) and overall survival (OS) were 76.3% and 82.7% respectively. In a multivariate analysis designed to avoid a collinearity bias with IPI categories, BMB-BMI [bone marrow involvement](+) (HR: 3.6) and ECOG PS > 1 (HR: 2.9) were independently associated with a shorter PFS and three factors, age >60 years old (HR: 2.4), ECOG PS >1 (HR: 2.4), and abnormally elevated B2-microglobulin levels (HR: 2.2) were independently associated with a shorter OS. In our DLBCL cohort, treated with a uniform first-line chemotherapy regimen, BMI by BMB complemented performance status in predicting those patients with a higher risk for relapse or progression. In this cohort BMI by PET/CT could not independently predict a shorter PFS and/or OS.
metadata.dc.identifier.doi: 10.1002/cam4.1205
Appears in Collections:Producción 2020

Files in This Item:
File SizeFormat 
PMC5673915.pdf256,97 kBAdobe PDFView/Open

This item is protected by original copyright

This item is licensed under a Creative Commons License Creative Commons